<DOC>
	<DOCNO>NCT00932282</DOCNO>
	<brief_summary>The purpose study determine whether addition anti-IgE treatment make peanut oral immunotherapy safer , tolerable , effective treat peanut allergy .</brief_summary>
	<brief_title>Peanut Oral Immunotherapy Anti-Immunoglobulin E ( IgE ) Peanut Allergy</brief_title>
	<detailed_description>The goal proposal produce new treatment would benefit subject peanut allergy lower risk anaphylactic reaction ( desensitization ) , change peanut-specific immune response subject peanut allergy ( tolerance ) . This project design study peanut oral immunotherapy ( OIT ) desensitize subject peanut hypersensitivity regulate oral systemic immune reactivity cause long-term tolerance . This study augment ongoing study look whether anti-IgE therapy reduce side effect allow accelerate build phase . Peanut allergic patient great 12 year old undergo omalizumab ( anti-IgE ) treatment 4 month prior peanut OIT , continue omalizumab one month maintenance therapy . Each subject initial desensitization phase 2 day goal 950 mg peanut powder follow build phase 4 month goal maintenance dose 8000 mg peanut powder . They randomize continue maintenance 12 24 month . They oral food challenge ( OFC ) immediately stop peanut OIT test desensitization . Four week later , OIT , another food challenge do assess tolerance . Outcome variables interest include result OFCs , pre post skin test , CAP-FEIA value basophil study . These result compare start point patient end study use appropriate statistical analysis .</detailed_description>
	<mesh_term>Hypersensitivity</mesh_term>
	<mesh_term>Peanut Hypersensitivity</mesh_term>
	<mesh_term>Omalizumab</mesh_term>
	<criteria>Age 12 year either sex , race , ethnicity time initial visit The presence IgE specific peanut ( positive skin prick test peanut ( diameter wheal &gt; 3.0 mm ) positive vitro IgE [ CAPFEIA ] &gt; 5 kUA/L A history significant clinical symptom ( urticaria , angioedema , rhinorrhea , nasal congestion , pruritis , sneeze , abdominal pain , emesis , diarrhea , wheeze , shortness breath , lip/tongue swelling , throat itching , throat swelling , impend sense doom ) occur within 60 minute ingest peanut Provide sign informed consent Women sexually active , must agree use appropriate contraceptive measure duration study 9 month afterwards History severe anaphylaxis peanut omalizumab define hypoxia , hypotension , neurological compromise ( Cyanosis oxygen saturation &lt; 92 % stage , hypotension , confusion , collapse , loss consciousness ; incontinence ) Currently participate study use investigational new drug Participation interventional study treatment food allergy past 12 month Subjects know oat wheat ( potential cross contamination oat ) food allergy exclude Poor control persistent activation atopic dermatitis Moderate severe persistent asthma Currently treat great medium daily dos inhaled corticosteroid , define National Heart Lung Blood Institute ( NHLBI ) guideline Inability discontinue antihistamine skin test oral food challenge ( OFCs ) History serious underlie disease ( i.e. , heart disease , diabetes , etc . ) Women pregnant nursing</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Peanut</keyword>
	<keyword>Allergy</keyword>
	<keyword>Hypersensitivity</keyword>
</DOC>